AtaiBeckley (ATAI) Receivables - Other (2020 - 2025)
AtaiBeckley recorded quarterly Receivables - Other of $326000.0 in Q3 2021, down 63.78% quarter-over-quarter from $900000.0 in Q4 2020.
AtaiBeckley has reported Receivables - Other for 1 years, with the latest figure at $300000.0 in Q4 2025.
- In Q3 2021, Receivables - Other changed N/A year-over-year to $326000.0; the TTM figure through Sep 2021 stood at $326000.0 (changed N/A YoY), while the FY2020 annual figure was $900000.0, changed N/A from the prior year.
- Receivables - Other for Q4 2025 stood at $300000.0.
- In the past five years, Receivables - Other ranged from a high of $900000.0 in Q4 2020 to a low of $326000.0 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | AtaiBeckley | 1.62 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2021 | 326,000.00 |
| Sep 30, 2021 | 326,000.00 |
| Dec 31, 2020 | 900,000.00 |
| Dec 31, 2020 | 900,000.00 |